Higher doses of semaglutide can safely enhance weight loss for adults living with obesity, clinical trials confirm

A higher weekly dose of semaglutide (7.2 mg) can significantly improve weight loss and related health outcomes in adults living with obesity, including those with type 2 diabetes (T2D), according to the results of two large-scale, international phase 3 clinical trials.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup